Miseviciene Valdone, Bojarskas Jurgis
Clinic of Children Diseases, Kaunas University of Medicine Hospital, Lithuania.
Medicina (Kaunas). 2003;39(3):217-20.
Bronchiolitis is the most common lower respiratory tract infection in infants and is responsible for the majority of pediatric hospital admissions in winter. Respiratory syncytial virus has been identified as the main causative agent, causing 50-90% of the cases of bronchiolitis. Despite significant advances in pharmacotherapy, the management of infants with bronchiolitis has changed little over the years from supplemental oxygen and good fluid management. Approaches to therapy vary widely all over the world and are controversial. This paper reviews current treatment options for bronchiolitis, including the use of bronchodilators, epinephrine, steroids and ribavirin. Most recent advances, including immunotherapy and intensive care, are discussed.
细支气管炎是婴儿最常见的下呼吸道感染,也是冬季大多数儿科住院病例的病因。呼吸道合胞病毒已被确认为主要病原体,导致50%至90%的细支气管炎病例。尽管药物治疗取得了重大进展,但多年来,细支气管炎婴儿的治疗方法从补充氧气和良好的液体管理方面变化不大。世界各地的治疗方法差异很大,且存在争议。本文综述了细支气管炎的当前治疗选择,包括使用支气管扩张剂、肾上腺素、类固醇和利巴韦林。还讨论了包括免疫疗法和重症监护在内的最新进展。